IP Library Granted Patent US 11,312,957
Granted Patent B2
US 11,312,957 · App. 16/523,411 · Granted Apr 26, 2022

Modified iRNA agents

Inventors: Muthiah Manoharan (Cambridge, MA); Venkitasamy Kesavan (Cambridge, MA); Kallanthottathil Rajeev (Cambridge, MA)
Assignee: Alnylam Pharmaceuticals, Inc.
C12N15/113A61K47/55A61K47/554C07H21/02C12N15/111C12N2310/11C12N2310/14C12N2310/315C12N2310/321C12N2310/323C12N2310/3515C12N2320/32C12N2320/51C12N2330/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,312,957
App. No.
16/523,411
Granted
Apr 26, 2022
Kind
B2
Abstract

The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.

Claims (37)

1. An RNA agent comprising a sense strand and an antisense strand, wherein one or more ribose replacement modification subunit (RRMS) comprising a ligand is incorporated into at least one of said strands, and wherein the RRMS is a cyclic carrier selected from the group consisting of hydroxyproline, piperidine, morpholine, piperazine, and decalin, and wherein the ligand is connected to the RRMS via a tethering moiety containing a C 1 -C 20 alkyl group and having at least one nitrogen atom.

2. The RNA agent of claim 1 , wherein the tethering moiety is a C 1 -C 20 alkyl group substituted with a —NHC(O)— group.

3. The RNA agent of claim 2 , wherein the tethering moiety is a C 1 -C 10 alkyl group substituted with a —NHC(O)— group.

4. The RNA agent of claim 1 , wherein the ligand comprises one or more carbohydrate moieties.

5. The RNA agent of claim 4 , wherein the carbohydrate moieties are monosaccharides, disaccharides, trisaccharides, tetrasaccharides, polysaccharides, or combinations thereof.

6. The RNA agent of claim 1 , wherein the ligand is selected from the group consisting of a mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, multivalent N-acetyl-galactosamine, N-acetyl-glucosamine, multivalent N-acetyl-glucosamine, multivalent mannose, multivalent fucose, glycosylated polyaminoacids, lactose, galactose, mannose, and combinations thereof.

7. The RNA agent of claim 1 , wherein the RRMS subunit is placed within 1, 2, or 3 positions of the 3′ or 5′ end of at least one of said strands.

8. The RNA agent of claim 1 , wherein at least two RRMS subunits are incorporated into at least one of said strands.

9. The RNA agent of claim 8 , wherein at least three RRMS subunits are incorporated into at least one of said strands.

10. An RNA agent comprising a sense strand and an antisense strand, wherein at least one subunit having a formula (I) is incorporated into at least one of said strands:

wherein:

X is N(CO)R 7 or NR 7 ;

Y is NR 8 , O, S, CR 9 R 10 , or absent;

Z is CR 11 R 12 or absent;

each of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is, independently, H, OR a , OR b , (CH 2 ) n R a , or (CH 2 ) n OR b , provided that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is OR a or OR b and that at least one of R 1 , R 2 , R 3 , R 4 , R 9 , and R 10 is (CH 2 ) n OR a or (CH 2 ) n OR b ;

each of R 5 , R 6 , R 11 , and R 12 is, independently, H, C 1 -C 6 alkyl optionally substituted with 1-3 R 13 , or C(O)NHR 7 ; or R 5 and R 11 together are C 3 -C 8 cycloalkyl optionally substituted with R 14 ,

R 7 is a ligand tethered through a tethering moiety containing a C 1 -C 20 alkyl group and having at least one nitrogen atom;

R 8 is C 1 -C 6 alkyl;

R 13 is hydroxy, C 1 -C 4 alkoxy, or halo;

R 14 is NR c R 7 ,

R a is H or

R b is H or

wherein the Strand in each occurrence is independently the sense strand or antisense strand of the iRNA agent;

each of A and C is, independently, O or S;

B is OH, O − , or

R c is H or C 1 -C 6 alkyl; and

n is 1-4.

11. The RNA agent of claim 10 , wherein Y is CR 9 R 10 , and Z is absent.

12. The RNA agent of claim 11 , wherein R 2 , R 3 , R 4 , R 5 , R 6 , and R 10 are H; R 1 is CH 2 OR a ; and R 9 is OR b .

13. The RNA agent of claim 10 , wherein the tethering moiety in R 7 is a C 1 -C 20 alkyl group substituted with a —NHC(O)— group.

14. The RNA agent of claim 13 , wherein the tethering moiety in R 7 is a C 1 -C 10 alkyl group substituted with a —NHC(O)— group.

15. The RNA agent of claim 10 , wherein the ligand comprises one or more carbohydrate moieties.

16. The RNA agent of claim 15 , wherein the carbohydrate moieties are monosaccharides, disaccharides, trisaccharides, tetrasaccharides, polysaccharides, or combinations thereof.

17. The RNA agent of claim 10 , wherein the ligand is selected from the group consisting of a mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, multivalent N-acetyl-galactosamine, N-acetyl-glucosamine, multivalent N-acetyl-glucosamine, multivalent mannose, multivalent fucose, glycosylated polyaminoacids, lactose, galactose, mannose, and combinations thereof.

18. The RNA agent of claim 10 , wherein the subunit having formula (I) is placed within 1, 2, or 3 positions of the 3′ or 5′ end of at least one of said strands.

19. The RNA agent of claim 10 , wherein at least two subunits having formula (I) are incorporated into at least one of said strands.

20. The RNA agent of claim 19 , wherein at least three subunits having formula (I) are incorporated into at least one of said strands.

Assignments (2)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2023
From: MANOHARAN, MUTHIAH; KESAVAN, VENKITASAMY; RAJEEV, KALLANTHOTTATHIL G.
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 063153/0963 →
Continuity (19)
Continuation 15906908 · Feb 27, 2018
Continuation 15170693 · Jun 1, 2016
Continuation 14281661 · May 19, 2014
Continuation 13849003 · Mar 22, 2013
Continuation 12714298 · Feb 26, 2010
Continuation 10916185 · Aug 10, 2004
Continuation In Part PCTUS2004011829 · Apr 16, 2004
Provisional Application 60518453 · Nov 7, 2003
Provisional Application 60510318 · Oct 10, 2003
Provisional Application 60510246 · Oct 9, 2003
Provisional Application 60506341 · Sep 26, 2003
Provisional Application 60503414 · Sep 15, 2003
Provisional Application 60494597 · Aug 11, 2003
Provisional Application 60493986 · Aug 8, 2003
Provisional Application 60469612 · May 9, 2003
Provisional Application 60465802 · Apr 25, 2003
Provisional Application 60465665 · Apr 25, 2003
Provisional Application 60463772 · Apr 17, 2003
Related Publication 20190345498A1 · Nov 14, 2019